Skip to content

Cormorant Asset Management, LP

Follow

13F filer, CIK 1583977, BOSTON, MA

Cormorant Asset Management, LP reported $1,489,258,905 across 60 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 54.82% of the portfolio.

Accepted , ingested 13F-HR 0001583977-26-000011

Period
2026-09-30
Reported value
$1.49B
Holdings
60
Top 10 weight
54.82%
New
13
Sold out
3

Largest buys vs the previous quarter

SecurityShares changeApprox. value
BLSMnew+3,614,034$67.4M
ETRAnew+3,365,533$37.9M
ATTOnew+1,788,815$30.7M
LTGOnew+1,815,740$30.3M
IRDnew+5,500,000$26.6M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
PRAXreduced-140,000-$40.8M
EWTXreduced-650,000-$26.4M
DMRAexited-1,000,000-$26M
ABVXreduced-250,000-$24.8M
DNTHreduced-250,000-$22M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001583977-26-000011, largest first. % of portfolio is the value over $1,489,258,905, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PBLSPARABILIS MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 4,615,612 shares; 2026Q3: 4,615,612 shares 4,615,612$149M10.01%0Timeline
PRAXPRAXIS PRECISION MEDICINES IQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,693,219 shares; 2025Q1: 1,745,000 shares; 2025Q2: 1,625,000 shares; 2025Q3: 1,000,000 shares; 2025Q4: 950,000 shares; 2026Q1: 885,500 shares; 2026Q2: 640,000 shares; 2026Q3: 500,000 shares 500,000$146M9.78%-140,000Timeline
RAPPRAPPORT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,940,921 shares; 2025Q1: 2,940,921 shares; 2025Q2: 2,940,921 shares; 2025Q3: 3,192,521 shares; 2025Q4: 3,027,521 shares; 2026Q1: 2,957,521 shares; 2026Q2: 2,657,521 shares; 2026Q3: 2,457,521 shares 2,457,521$82.6M5.54%-200,000Timeline
EWTXEDGEWISE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,406,534 shares; 2025Q1: 4,101,992 shares; 2025Q2: 4,251,992 shares; 2025Q3: 4,010,000 shares; 2025Q4: 3,285,000 shares; 2026Q1: 3,260,000 shares; 2026Q2: 2,510,000 shares; 2026Q3: 1,860,000 shares 1,860,000$75.5M5.07%-650,000Timeline
BBOTBRIDGEBIO ONCOLOGY THERAPEUTQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 17,878,594 shares; 2025Q4: 17,878,594 shares; 2026Q1: 17,878,594 shares; 2026Q2: 17,878,594 shares; 2026Q3: 17,878,594 shares 17,878,594$73.3M4.92%0Timeline
ERASERASCA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 5,800,000 shares; 2026Q2: 6,000,000 shares; 2026Q3: 5,000,000 shares 5,000,000$73.3M4.92%-1,000,000Timeline
BLSMBLOSSOMHILL THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 3,614,034 shares 3,614,034$67.4M4.52%newTimeline
ANLADLAI NORTYE GROUP LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,897,857 shares; 2026Q2: 3,978,229 shares; 2026Q3: 3,978,229 shares 3,978,229$63.7M4.27%0Timeline
DNTHDIANTHUS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 950,000 shares; 2026Q2: 750,000 shares; 2026Q3: 500,000 shares 500,000$44M2.96%-250,000Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,130,000 shares; 2025Q1: 2,130,000 shares; 2025Q2: 2,130,000 shares; 2025Q3: 1,950,000 shares; 2025Q4: 1,350,000 shares; 2026Q1: 760,000 shares; 2026Q2: 675,000 shares; 2026Q3: 425,000 shares 425,000$42.1M2.83%-250,000Timeline
DRUGBRIGHT MINDS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,059,331 shares; 2025Q1: 1,059,331 shares; 2025Q2: 1,059,331 shares; 2025Q3: 1,059,331 shares; 2025Q4: 1,059,331 shares; 2026Q1: 1,059,331 shares; 2026Q2: 900,000 shares; 2026Q3: 800,000 shares 800,000$39.9M2.68%-100,000Timeline
ETRAELECTRA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 3,365,533 shares 3,365,533$37.9M2.54%newTimeline
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 8,494,151 shares; 2025Q1: 8,494,151 shares; 2025Q2: 8,494,151 shares; 2025Q3: 1,994,173 shares; 2025Q4: 4,355,433 shares; 2026Q1: 4,480,433 shares; 2026Q2: 3,205,433 shares; 2026Q3: 2,855,433 shares 2,855,433$33.4M2.24%-350,000Timeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 533,340 shares; 2025Q4: 533,340 shares; 2026Q1: 533,340 shares; 2026Q2: 533,340 shares; 2026Q3: 400,000 shares 400,000$33.3M2.24%-133,340Timeline
ATTOATTOVIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,788,815 shares 1,788,815$30.7M2.06%newTimeline
FTHFAETH THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 306,222 shares; 2026Q2: 1,028,242 shares; 2026Q3: 1,028,242 shares 1,028,242$30.6M2.05%0Timeline
LTGOLATIGO BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,815,740 shares 1,815,740$30.3M2.04%newTimeline
AGMBAGOMAB THERAPEUTICS NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,465,348 shares; 2026Q2: 2,465,348 shares; 2026Q3: 2,465,348 shares 2,465,348$27.4M1.84%0Timeline
IRDOPUS GENETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 5,500,000 shares 5,500,000$26.6M1.79%newTimeline
CLYMCLIMB BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 2,106,000 shares; 2026Q3: 2,106,000 shares 2,106,000$24.2M1.62%0Timeline
FRNMFREENOME INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,431,032 shares 1,431,032$22.5M1.51%newTimeline
MBXMBX BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 700,000 shares; 2025Q1: 700,000 shares; 2025Q2: 700,000 shares; 2025Q3: 1,225,000 shares; 2025Q4: 1,120,000 shares; 2026Q1: 1,120,000 shares; 2026Q2: 550,000 shares; 2026Q3: 375,000 shares 375,000$22M1.48%-175,000Timeline
BHVNBIOHAVEN LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 55,539 shares; 2025Q1: 10,000 shares; 2025Q2: 10,000 shares; 2025Q3: 10,000 shares; 2025Q4: 10,000 shares; 2026Q1: 1,760,000 shares; 2026Q2: 2,610,000 shares; 2026Q3: 1,510,000 shares 1,510,000$20.2M1.35%-1,100,000Timeline
ADRXADARX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 962,898 shares 962,898$19.2M1.29%newTimeline
EYPTEYEPOINT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 8,325,000 shares; 2025Q1: 8,325,000 shares; 2025Q2: 8,325,000 shares; 2025Q3: 8,325,000 shares; 2025Q4: 8,265,000 shares; 2026Q1: 8,265,000 shares; 2026Q2: 7,000,000 shares; 2026Q3: 5,750,000 shares 5,750,000$18.8M1.26%-1,250,000Timeline
TNGXTANGO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,425,000 shares; 2026Q2: 1,300,000 shares; 2026Q3: 700,000 shares 700,000$17.5M1.17%-600,000Timeline
DMRADAMORA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 800,000 shares 800,000$17M1.14%newTimeline
BBIOBRIDGEBIO PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,600,000 shares; 2025Q1: 2,000,000 shares; 2025Q2: 1,600,000 shares; 2025Q3: 1,400,000 shares; 2025Q4: 1,200,000 shares; 2026Q1: 850,000 shares; 2026Q2: 550,000 shares; 2026Q3: 250,000 shares 250,000$16.4M1.1%-300,000Timeline
CUECUE BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 625,285 shares 625,285$16.2M1.09%newTimeline
CRBPCORBUS PHARMACEUTICALS HLDGSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,375,000 shares; 2025Q1: 2,375,000 shares; 2025Q2: 2,375,000 shares; 2025Q3: 2,375,000 shares; 2025Q4: 2,344,971 shares; 2026Q1: 2,344,971 shares; 2026Q2: 2,344,971 shares; 2026Q3: 2,344,971 shares 2,344,971$16M1.07%02026-10-31, 13G/A: 1,500,000 shares, 7.76% of the class, 13G/A filed 2026-11-02 Timeline
BIOABIOAGE LABS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,629,529 shares; 2025Q1: 2,629,529 shares; 2025Q2: 2,140,605 shares; 2025Q3: 2,140,605 shares; 2025Q4: 2,040,605 shares; 2026Q1: 2,890,605 shares; 2026Q2: 2,390,605 shares; 2026Q3: 2,240,605 shares 2,240,605$15.9M1.07%-150,000Timeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,147,396 shares; 2025Q1: 2,147,396 shares; 2025Q2: 2,147,396 shares; 2025Q3: 2,147,396 shares; 2025Q4: 3,635,596 shares; 2026Q1: 3,949,241 shares; 2026Q2: 3,285,596 shares; 2026Q3: 2,075,000 shares 2,075,000$15.3M1.03%-1,210,596Timeline
OLMAOLEMA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 2,750,000 shares; 2026Q1: 3,900,000 shares; 2026Q2: 2,150,000 shares; 2026Q3: 1,750,000 shares 1,750,000$15.1M1.02%-400,000Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,466,460 shares; 2025Q1: 1,466,460 shares; 2025Q2: 1,454,660 shares; 2025Q3: 1,363,200 shares; 2025Q4: 1,083,000 shares; 2026Q1: 1,000,000 shares; 2026Q2: 750,000 shares; 2026Q3: 450,000 shares 450,000$14.3M0.96%-300,000Timeline
HLXCHELIX ACQUISITION CORP IIIQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,297,500 shares; 2026Q2: 1,297,500 shares; 2026Q3: 1,297,500 shares 1,297,500$13.8M0.93%0Timeline
SYRESPYRE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 225,000 shares; 2026Q3: 125,000 shares 125,000$11.1M0.75%-100,000Timeline
DFTXDEFINIUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 400,000 shares; 2026Q3: 275,000 shares 275,000$10.5M0.7%-125,000Timeline
ACRSACLARIS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,750,000 shares 1,750,000$9.21M0.62%newTimeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 500,000 shares; 2025Q4: 400,000 shares; 2026Q1: 350,000 shares; 2026Q2: 200,000 shares; 2026Q3: 300,000 shares 300,000$8.73M0.59%+100,000Timeline
CABACABALETTA BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 5,000,000 shares; 2025Q3: 5,000,000 shares; 2025Q4: 4,400,000 shares; 2026Q1: 5,500,000 shares; 2026Q2: 5,000,000 shares; 2026Q3: 4,500,000 shares 4,500,000$8.64M0.58%-500,000Timeline
INBXINHIBRX BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 50,000 shares 50,000$5M0.34%newTimeline
KLRAKAILERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 550,000 shares; 2026Q3: 400,000 shares 400,000$4.57M0.31%-150,000Timeline
JBIOJADE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 300,000 shares 300,000$4.21M0.28%newTimeline
IBIOIBIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 3,570,000 shares; 2026Q3: 3,570,000 shares 3,570,000$4.21M0.28%0Timeline
TARSTARSUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 500,000 shares; 2025Q1: 400,000 shares; 2025Q2: 300,000 shares; 2025Q3: 300,000 shares; 2025Q4: 250,000 shares; 2026Q1: 225,000 shares; 2026Q2: 100,000 shares; 2026Q3: 50,000 shares 50,000$3.93M0.26%-50,000Timeline
ROIVROIVANT SCIENCES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 750,000 shares; 2026Q2: 475,000 shares; 2026Q3: 100,000 shares 100,000$3.66M0.25%-375,000Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 250,000 shares; 2025Q1: 250,000 shares; 2025Q2: 200,000 shares; 2025Q3: 200,000 shares; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 150,000 shares; 2026Q3: 75,000 shares 75,000$3.44M0.23%-75,000Timeline
ASNDASCENDIS PHARMA A/SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 50,000 shares; 2026Q3: 15,000 shares 15,000$3.42M0.23%-35,000Timeline
ODTXODYSSEY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 175,000 shares; 2026Q3: 125,000 shares 125,000$2.78M0.19%-50,000Timeline
NAMSNEWAMSTERDAM PHARMA COMPANYQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,250,000 shares; 2025Q1: 2,825,000 shares; 2025Q2: 2,175,000 shares; 2025Q3: 2,175,000 shares; 2025Q4: 1,000,000 shares; 2026Q1: 950,000 shares; 2026Q2: 500,000 shares; 2026Q3: 100,000 shares 100,000$2.43M0.16%-400,000Timeline
BOLDBOUNDLESS BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,000,000 shares; 2026Q3: 940,000 shares 940,000$2.36M0.16%-60,000Timeline
INSMINSMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 650,000 shares; 2025Q1: 525,000 shares; 2025Q2: 540,000 shares; 2025Q3: 430,000 shares; 2025Q4: 275,000 shares; 2026Q1: 190,000 shares; 2026Q2: 75,000 shares; 2026Q3: 20,000 shares 20,000$2.28M0.15%-55,000Timeline
BRVEBRAVEHEART BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 70,000 shares 70,000$1.41M0.09%newTimeline
RACCRESEARCH ALLIANCE CORP IIIQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 370,000 shares; 2026Q3: 125,000 shares 125,000$1.35M0.09%-245,000Timeline
ARQTARCUTIS BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,825,000 shares; 2025Q1: 1,350,000 shares; 2025Q2: 1,000,000 shares; 2025Q3: 775,000 shares; 2025Q4: 500,000 shares; 2026Q1: 450,000 shares; 2026Q2: 175,000 shares; 2026Q3: 50,000 shares 50,000$1.32M0.09%-125,000Timeline
ARWRARROWHEAD PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 100,000 shares; 2026Q2: 50,000 shares; 2026Q3: 15,000 shares 15,000$982K0.07%-35,000Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 225,000 shares; 2026Q1: 200,000 shares; 2026Q2: 100,000 shares; 2026Q3: 30,000 shares 30,000$961K0.06%-70,000Timeline
GPCRSTRUCTURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 175,000 shares; 2026Q2: 75,000 shares; 2026Q3: 30,000 shares 30,000$938K0.06%-45,000Timeline
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 425,000 shares; 2025Q1: 175,000 shares; 2025Q2: 175,000 shares; 2025Q3: 175,000 shares; 2025Q4: 125,000 shares; 2026Q1: 100,000 shares; 2026Q2: 50,000 shares; 2026Q3: 15,000 shares 15,000$854K0.06%-35,000Timeline
IRLAQUINCE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 5,498 shares; 2026Q3: 5,498 shares 5,498$170K0.01%0Timeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
DMRADAMORA THERAPEUTICS INC1,000,000$26Mshares
CRNXCRINETICS PHARMACEUTICALS IN125,000$4.68Mshares
ALTALTIMMUNE INC1,250,000$3.8Mshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001583977-26-000011 base2026-11-16